<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353508</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B2223</org_study_id>
    <nct_id>NCT01353508</nct_id>
  </id_info>
  <brief_title>Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Assess mechanism of action of LCZ696 related to sodium excretion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Urinary Sodium Excretion</measure>
    <time_frame>day 1</time_frame>
    <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative 7-day Urinary Sodium Excretion</measure>
    <time_frame>7 day-cummulative (days 1 through 7)</time_frame>
    <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour Diuresis</measure>
    <time_frame>day 1</time_frame>
    <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Cumulative Diuresis</measure>
    <time_frame>7-day cumulative (days 1 through 7)</time_frame>
    <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours</measure>
    <time_frame>day 1, day 6, day 7</time_frame>
    <description>cGMP was analyzed at a central laboratory. The measure type used for this OM was Geometric LSM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker</measure>
    <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 2, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>MR-proANP was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker</measure>
    <time_frame>0.5, 1, 2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>BNP was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker</measure>
    <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>MR-proADM was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker</measure>
    <time_frame>2, 4, 6, 8 and 12 hours post dose on day 1; day 2; 0, 4, 6, 8 and 12 hours post dose on day 7</time_frame>
    <description>ProCNP was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker</measure>
    <time_frame>12 hours post dose on day 1; 24 hours post dose on day 2; 0 and 12 hours post dose on day 7</time_frame>
    <description>CT-proET-1 was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker</measure>
    <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>NT-proBNP was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Aldosterone Biomarker</measure>
    <time_frame>6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 6 and 12 hours post dose on day 7</time_frame>
    <description>Aldosterone was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)</measure>
    <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium, potassium, albumin and calcium were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Blood Plasma Creatinine</measure>
    <time_frame>4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
    <description>Blood plasma creatinine was analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) Over Time</measure>
    <time_frame>0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7</time_frame>
    <description>GFR was used as a measure of renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Blood Flow (RBF) Over Time</measure>
    <time_frame>0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7</time_frame>
    <description>RBF was used as a measure of renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Systolic Blood Pressure</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
    <description>Systolic blood pressure measurements were taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Diastolic Blood Pressure</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
    <description>Diastolic blood pressure measurements were taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Pulse Rate</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
    <description>Pulse rate measurements were taken.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 to Valsartan - Heart Failure (HF) cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan to LCZ696 - HF Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 to Valsartan - Hypertension (HTN) cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan to LCZ696 - HTN cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>200 mg and 400 mg tablets</description>
    <arm_group_label>LCZ696 to Valsartan - Heart Failure (HF) cohort</arm_group_label>
    <arm_group_label>Valsartan to LCZ696 - HF Cohort</arm_group_label>
    <arm_group_label>LCZ696 to Valsartan - Hypertension (HTN) cohort</arm_group_label>
    <arm_group_label>Valsartan to LCZ696 - HTN cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>160 mg tablets</description>
    <arm_group_label>LCZ696 to Valsartan - Heart Failure (HF) cohort</arm_group_label>
    <arm_group_label>Valsartan to LCZ696 - HF Cohort</arm_group_label>
    <arm_group_label>LCZ696 to Valsartan - Hypertension (HTN) cohort</arm_group_label>
    <arm_group_label>Valsartan to LCZ696 - HTN cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with heart failure: documented NYHA class II-III heart failure

          -  Patients with hypertension: stable hypertensive medication for the preceding 2 months

        Exclusion Criteria:

          -  Women of childbearing potential

          -  History of recent myocardial infarction

          -  History of dialysis or renal transplant

          -  Patients with type 1 diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <results_first_submitted>July 15, 2015</results_first_submitted>
  <results_first_submitted_qc>October 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2015</results_first_posted>
  <disposition_first_submitted>January 21, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 21, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 14, 2014</disposition_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sodium excretion,</keyword>
  <keyword>LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In each of the HF and HTN cohorts, 16 participants (total = 32) received LCZ696 or Valsartan in period 1. Then, there was a cross-over where participants received LCZ96 or Valsartan in period 2.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 to Valsartan - Heart Failure (HF) Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="P2">
          <title>Valsartan to LCZ696 - HF Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="P3">
          <title>LCZ696 to Valsartan - Hypertension (HTN) Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
        </group>
        <group group_id="P4">
          <title>Valsartan to LCZ696 - HTN Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - First Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Second Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 to Valsartan - Heart Failure (HF) Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="B2">
          <title>Valsartan to LCZ696 - HF Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="B3">
          <title>LCZ696 to Valsartan - Hypertension (HTN) Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
        </group>
        <group group_id="B4">
          <title>Valsartan to LCZ696 - HTN Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age mean and standard deviation (SD) for HF cohort was 65.4 (9.57); age mean and SD for HTN cohort was 58.8 (8.15)</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="10.15"/>
                    <measurement group_id="B2" value="67.6" spread="9.07"/>
                    <measurement group_id="B3" value="58.0" spread="8.02"/>
                    <measurement group_id="B4" value="61.6" spread="8.40"/>
                    <measurement group_id="B5" value="62.6" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-hour Urinary Sodium Excretion</title>
        <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
        <time_frame>day 1</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Urinary Sodium Excretion</title>
          <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mmol/24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.58" lower_limit="182.64" upper_limit="266.41"/>
                    <measurement group_id="O2" value="198.73" lower_limit="163.50" upper_limit="241.56"/>
                    <measurement group_id="O3" value="177.40" lower_limit="152.65" upper_limit="206.15"/>
                    <measurement group_id="O4" value="146.18" lower_limit="126.42" upper_limit="169.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative 7-day Urinary Sodium Excretion</title>
        <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
        <time_frame>7 day-cummulative (days 1 through 7)</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative 7-day Urinary Sodium Excretion</title>
          <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mmol/7 days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020.57" lower_limit="903.47" upper_limit="1152.84"/>
                    <measurement group_id="O2" value="1114.18" lower_limit="983.37" upper_limit="1262.39"/>
                    <measurement group_id="O3" value="906.81" lower_limit="839.94" upper_limit="979.00"/>
                    <measurement group_id="O4" value="943.26" lower_limit="873.62" upper_limit="1018.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Diuresis</title>
        <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
        <time_frame>day 1</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Diuresis</title>
          <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mL/24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3199.37" lower_limit="2662.17" upper_limit="3844.96"/>
                    <measurement group_id="O2" value="2874.36" lower_limit="2375.61" upper_limit="3477.82"/>
                    <measurement group_id="O3" value="3382.94" lower_limit="2859.86" upper_limit="4001.70"/>
                    <measurement group_id="O4" value="2393.61" lower_limit="2034.84" upper_limit="2815.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Cumulative Diuresis</title>
        <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
        <time_frame>7-day cumulative (days 1 through 7)</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Cumulative Diuresis</title>
          <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12347.92" lower_limit="10842.81" upper_limit="14062.48"/>
                    <measurement group_id="O2" value="13180.02" lower_limit="11539.55" upper_limit="15053.71"/>
                    <measurement group_id="O3" value="16980.05" lower_limit="15627.59" upper_limit="18449.54"/>
                    <measurement group_id="O4" value="15265.35" lower_limit="14048.28" upper_limit="16587.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours</title>
        <description>cGMP was analyzed at a central laboratory. The measure type used for this OM was Geometric LSM.</description>
        <time_frame>day 1, day 6, day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours</title>
          <description>cGMP was analyzed at a central laboratory. The measure type used for this OM was Geometric LSM.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>nmol/24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1851.79" lower_limit="1504.96" upper_limit="2278.56"/>
                    <measurement group_id="O2" value="884.99" lower_limit="713.93" upper_limit="1097.03"/>
                    <measurement group_id="O3" value="1085.76" lower_limit="867.64" upper_limit="1358.71"/>
                    <measurement group_id="O4" value="557.53" lower_limit="448.87" upper_limit="692.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1467.67" lower_limit="1153.25" upper_limit="1867.79"/>
                    <measurement group_id="O2" value="865.62" lower_limit="674.39" upper_limit="1111.07"/>
                    <measurement group_id="O3" value="863.32" lower_limit="707.64" upper_limit="1053.25"/>
                    <measurement group_id="O4" value="562.11" lower_limit="460.85" upper_limit="685.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1571.02" lower_limit="1331.84" upper_limit="1853.15"/>
                    <measurement group_id="O2" value="859.07" lower_limit="723.03" upper_limit="1020.72"/>
                    <measurement group_id="O3" value="1107.04" lower_limit="869.95" upper_limit="1408.76"/>
                    <measurement group_id="O4" value="603.90" lower_limit="474.68" upper_limit="768.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker</title>
        <description>MR-proANP was analyzed at a central laboratory.</description>
        <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 2, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker</title>
          <description>MR-proANP was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.04" lower_limit="-12.21" upper_limit="-1.87"/>
                    <measurement group_id="O2" value="2.08" lower_limit="-3.48" upper_limit="7.63"/>
                    <measurement group_id="O3" value="-10.11" lower_limit="-17.41" upper_limit="-2.82"/>
                    <measurement group_id="O4" value="-1.66" lower_limit="-7.99" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.39" lower_limit="-24.68" upper_limit="-10.10"/>
                    <measurement group_id="O2" value="-6.74" lower_limit="-14.32" upper_limit="0.84"/>
                    <measurement group_id="O3" value="-12.68" lower_limit="-25.45" upper_limit="0.08"/>
                    <measurement group_id="O4" value="-7.33" lower_limit="-19.27" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.99" lower_limit="-31.64" upper_limit="-16.33"/>
                    <measurement group_id="O2" value="-10.16" lower_limit="-18.08" upper_limit="-2.23"/>
                    <measurement group_id="O3" value="-17.82" lower_limit="-25.16" upper_limit="-10.48"/>
                    <measurement group_id="O4" value="-4.52" lower_limit="-11.60" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.58" lower_limit="-38.93" upper_limit="-16.22"/>
                    <measurement group_id="O2" value="-7.48" lower_limit="-19.26" upper_limit="4.29"/>
                    <measurement group_id="O3" value="-19.77" lower_limit="-32.56" upper_limit="-6.98"/>
                    <measurement group_id="O4" value="-15.20" lower_limit="-27.10" upper_limit="-3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.13" lower_limit="-35.53" upper_limit="-14.73"/>
                    <measurement group_id="O2" value="-14.53" lower_limit="-25.28" upper_limit="-3.78"/>
                    <measurement group_id="O3" value="-17.30" lower_limit="-33.46" upper_limit="-1.13"/>
                    <measurement group_id="O4" value="-9.45" lower_limit="-24.39" upper_limit="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.27" lower_limit="-29.72" upper_limit="-12.81"/>
                    <measurement group_id="O2" value="-2.54" lower_limit="-11.30" upper_limit="6.21"/>
                    <measurement group_id="O3" value="-16.03" lower_limit="-28.52" upper_limit="-3.53"/>
                    <measurement group_id="O4" value="0.44" lower_limit="-11.59" upper_limit="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.35" lower_limit="-35.18" upper_limit="-13.52"/>
                    <measurement group_id="O2" value="1.64" lower_limit="-9.62" upper_limit="12.91"/>
                    <measurement group_id="O3" value="-19.34" lower_limit="-31.20" upper_limit="-7.49"/>
                    <measurement group_id="O4" value="-2.56" lower_limit="-13.90" upper_limit="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.40" lower_limit="-33.98" upper_limit="-12.82"/>
                    <measurement group_id="O2" value="-3.53" lower_limit="-14.54" upper_limit="7.48"/>
                    <measurement group_id="O3" value="-20.84" lower_limit="-33.62" upper_limit="-8.05"/>
                    <measurement group_id="O4" value="-1.98" lower_limit="-14.25" upper_limit="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.95" lower_limit="-33.10" upper_limit="-8.80"/>
                    <measurement group_id="O2" value="-12.65" lower_limit="-25.27" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="-23.09" lower_limit="-35.90" upper_limit="-10.28"/>
                    <measurement group_id="O4" value="-10.27" lower_limit="-22.61" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker</title>
        <description>BNP was analyzed at a central laboratory.</description>
        <time_frame>0.5, 1, 2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker</title>
          <description>BNP was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.32" lower_limit="-70.26" upper_limit="214.90"/>
                    <measurement group_id="O2" value="-8.93" lower_limit="-151.85" upper_limit="133.99"/>
                    <measurement group_id="O3" value="-10.75" lower_limit="-28.59" upper_limit="7.08"/>
                    <measurement group_id="O4" value="-5.94" lower_limit="-23.59" upper_limit="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.0 hr post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.85" lower_limit="-86.02" upper_limit="329.72"/>
                    <measurement group_id="O2" value="-0.83" lower_limit="-209.19" upper_limit="207.53"/>
                    <measurement group_id="O3" value="1218.56" lower_limit="-760.23" upper_limit="3197.35"/>
                    <measurement group_id="O4" value="-33.19" lower_limit="-1865.92" upper_limit="1799.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.35" lower_limit="-85.34" upper_limit="438.04"/>
                    <measurement group_id="O2" value="21.92" lower_limit="-215.63" upper_limit="259.47"/>
                    <measurement group_id="O3" value="31.10" lower_limit="8.44" upper_limit="53.76"/>
                    <measurement group_id="O4" value="-0.38" lower_limit="-21.37" upper_limit="20.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.12" lower_limit="30.22" upper_limit="70.02"/>
                    <measurement group_id="O2" value="-1.78" lower_limit="-21.01" upper_limit="17.44"/>
                    <measurement group_id="O3" value="38.82" lower_limit="18.71" upper_limit="58.92"/>
                    <measurement group_id="O4" value="11.06" lower_limit="-7.56" upper_limit="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.62" lower_limit="-10.46" upper_limit="271.70"/>
                    <measurement group_id="O2" value="11.09" lower_limit="-130.33" upper_limit="152.51"/>
                    <measurement group_id="O3" value="68.23" lower_limit="11.48" upper_limit="124.97"/>
                    <measurement group_id="O4" value="7.97" lower_limit="-44.59" upper_limit="60.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.58" lower_limit="28.51" upper_limit="152.66"/>
                    <measurement group_id="O2" value="30.07" lower_limit="-32.15" upper_limit="92.29"/>
                    <measurement group_id="O3" value="85.93" lower_limit="23.34" upper_limit="148.52"/>
                    <measurement group_id="O4" value="8.51" lower_limit="-48.97" upper_limit="65.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.88" lower_limit="-84.18" upper_limit="289.93"/>
                    <measurement group_id="O2" value="5.18" lower_limit="-174.46" upper_limit="184.81"/>
                    <measurement group_id="O3" value="-0.66" lower_limit="-31.34" upper_limit="30.02"/>
                    <measurement group_id="O4" value="-20.61" lower_limit="-47.16" upper_limit="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.96" lower_limit="-100.59" upper_limit="482.51"/>
                    <measurement group_id="O2" value="27.75" lower_limit="-264.49" upper_limit="320.00"/>
                    <measurement group_id="O3" value="14.20" lower_limit="-28.81" upper_limit="57.21"/>
                    <measurement group_id="O4" value="-7.19" lower_limit="-48.17" upper_limit="33.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.38" lower_limit="-72.28" upper_limit="513.04"/>
                    <measurement group_id="O2" value="34.44" lower_limit="-249.44" upper_limit="318.31"/>
                    <measurement group_id="O3" value="34.92" lower_limit="-6.58" upper_limit="76.42"/>
                    <measurement group_id="O4" value="5.20" lower_limit="-34.59" upper_limit="44.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.06" lower_limit="-94.90" upper_limit="485.02"/>
                    <measurement group_id="O2" value="46.75" lower_limit="-257.14" upper_limit="350.63"/>
                    <measurement group_id="O3" value="7.78" lower_limit="-33.49" upper_limit="49.04"/>
                    <measurement group_id="O4" value="7.82" lower_limit="-29.68" upper_limit="45.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.05" lower_limit="-173.38" upper_limit="645.47"/>
                    <measurement group_id="O2" value="70.31" lower_limit="-334.37" upper_limit="474.99"/>
                    <measurement group_id="O3" value="38.45" lower_limit="-13.98" upper_limit="90.88"/>
                    <measurement group_id="O4" value="25.79" lower_limit="-24.48" upper_limit="76.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker</title>
        <description>MR-proADM was analyzed at a central laboratory.</description>
        <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker</title>
          <description>MR-proADM was analyzed at a central laboratory.</description>
          <population>The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" lower_limit="-0.34" upper_limit="16.42"/>
                    <measurement group_id="O2" value="-2.87" lower_limit="-11.53" upper_limit="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" lower_limit="11.38" upper_limit="31.06"/>
                    <measurement group_id="O2" value="-8.22" lower_limit="-18.03" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.18" lower_limit="10.05" upper_limit="30.31"/>
                    <measurement group_id="O2" value="-8.81" lower_limit="-18.90" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.70" lower_limit="22.25" upper_limit="59.15"/>
                    <measurement group_id="O2" value="7.61" lower_limit="-10.84" upper_limit="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.28" lower_limit="42.29" upper_limit="72.26"/>
                    <measurement group_id="O2" value="0.72" lower_limit="-14.26" upper_limit="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.28" lower_limit="47.35" upper_limit="75.21"/>
                    <measurement group_id="O2" value="1.38" lower_limit="-12.07" upper_limit="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.71" lower_limit="39.67" upper_limit="63.74"/>
                    <measurement group_id="O2" value="-5.27" lower_limit="-16.90" upper_limit="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.22" lower_limit="36.26" upper_limit="60.19"/>
                    <measurement group_id="O2" value="-3.63" lower_limit="-14.89" upper_limit="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.45" lower_limit="50.70" upper_limit="88.20"/>
                    <measurement group_id="O2" value="2.15" lower_limit="-16.60" upper_limit="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker</title>
        <description>ProCNP was analyzed at a central laboratory.</description>
        <time_frame>2, 4, 6, 8 and 12 hours post dose on day 1; day 2; 0, 4, 6, 8 and 12 hours post dose on day 7</time_frame>
        <population>The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker</title>
          <description>ProCNP was analyzed at a central laboratory.</description>
          <population>The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="-6.33" upper_limit="7.03"/>
                    <measurement group_id="O2" value="-1.01" lower_limit="-8.16" upper_limit="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.58" lower_limit="19.36" upper_limit="49.79"/>
                    <measurement group_id="O2" value="-6.02" lower_limit="-22.28" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.85" lower_limit="42.32" upper_limit="93.37"/>
                    <measurement group_id="O2" value="-16.19" lower_limit="-43.85" upper_limit="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.75" lower_limit="87.53" upper_limit="159.98"/>
                    <measurement group_id="O2" value="-9.87" lower_limit="-48.59" upper_limit="28.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.36" lower_limit="148.95" upper_limit="231.78"/>
                    <measurement group_id="O2" value="15.55" lower_limit="-29.00" upper_limit="60.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.81" lower_limit="163.62" upper_limit="274.01"/>
                    <measurement group_id="O2" value="4.99" lower_limit="-54.79" upper_limit="64.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.20" lower_limit="186.26" upper_limit="302.14"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-61.85" upper_limit="62.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.61" lower_limit="159.66" upper_limit="273.56"/>
                    <measurement group_id="O2" value="-8.94" lower_limit="-69.82" upper_limit="51.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.21" lower_limit="151.36" upper_limit="271.07"/>
                    <measurement group_id="O2" value="-18.17" lower_limit="-82.15" upper_limit="45.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.99" lower_limit="181.22" upper_limit="302.76"/>
                    <measurement group_id="O2" value="-11.30" lower_limit="-76.27" upper_limit="53.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.58" lower_limit="214.45" upper_limit="342.71"/>
                    <measurement group_id="O2" value="0.88" lower_limit="-67.68" upper_limit="69.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker</title>
        <description>CT-proET-1 was analyzed at a central laboratory.</description>
        <time_frame>12 hours post dose on day 1; 24 hours post dose on day 2; 0 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker</title>
          <description>CT-proET-1 was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.39" lower_limit="26.14" upper_limit="46.65"/>
                    <measurement group_id="O2" value="2.51" lower_limit="-8.14" upper_limit="13.16"/>
                    <measurement group_id="O3" value="108.87" lower_limit="5.82" upper_limit="211.92"/>
                    <measurement group_id="O4" value="54.07" lower_limit="-38.42" upper_limit="146.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.44" lower_limit="19.41" upper_limit="45.47"/>
                    <measurement group_id="O2" value="11.41" lower_limit="-2.76" upper_limit="25.59"/>
                    <measurement group_id="O3" value="123.45" lower_limit="36.65" upper_limit="210.25"/>
                    <measurement group_id="O4" value="38.70" lower_limit="-41.78" upper_limit="119.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.98" lower_limit="19.53" upper_limit="44.42"/>
                    <measurement group_id="O2" value="0.62" lower_limit="-11.85" upper_limit="13.09"/>
                    <measurement group_id="O3" value="94.76" lower_limit="17.45" upper_limit="172.06"/>
                    <measurement group_id="O4" value="41.77" lower_limit="-32.97" upper_limit="116.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.75" lower_limit="26.81" upper_limit="56.69"/>
                    <measurement group_id="O2" value="7.05" lower_limit="-8.97" upper_limit="23.08"/>
                    <measurement group_id="O3" value="117.84" lower_limit="30.76" upper_limit="204.92"/>
                    <measurement group_id="O4" value="61.90" lower_limit="-22.40" upper_limit="146.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker</title>
        <description>NT-proBNP was analyzed at a central laboratory.</description>
        <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker</title>
          <description>NT-proBNP was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" lower_limit="-1.80" upper_limit="7.92"/>
                    <measurement group_id="O2" value="6.87" lower_limit="1.87" upper_limit="11.88"/>
                    <measurement group_id="O3" value="5.10" lower_limit="-1.10" upper_limit="11.31"/>
                    <measurement group_id="O4" value="8.32" lower_limit="2.32" upper_limit="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="-5.30" upper_limit="10.66"/>
                    <measurement group_id="O2" value="13.21" lower_limit="5.02" upper_limit="21.40"/>
                    <measurement group_id="O3" value="44.79" lower_limit="-11.93" upper_limit="101.51"/>
                    <measurement group_id="O4" value="22.14" lower_limit="-32.65" upper_limit="76.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="-8.15" upper_limit="15.57"/>
                    <measurement group_id="O2" value="21.70" lower_limit="9.59" upper_limit="33.80"/>
                    <measurement group_id="O3" value="12.58" lower_limit="-4.17" upper_limit="29.33"/>
                    <measurement group_id="O4" value="21.21" lower_limit="5.03" upper_limit="37.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.15" lower_limit="-3.58" upper_limit="37.89"/>
                    <measurement group_id="O2" value="42.32" lower_limit="20.94" upper_limit="63.70"/>
                    <measurement group_id="O3" value="61.46" lower_limit="3.83" upper_limit="119.09"/>
                    <measurement group_id="O4" value="33.17" lower_limit="-22.28" upper_limit="88.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.85" lower_limit="-35.37" upper_limit="-8.33"/>
                    <measurement group_id="O2" value="23.51" lower_limit="9.48" upper_limit="37.54"/>
                    <measurement group_id="O3" value="8.61" lower_limit="-20.73" upper_limit="37.95"/>
                    <measurement group_id="O4" value="-4.41" lower_limit="-32.64" upper_limit="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.57" lower_limit="-34.08" upper_limit="-5.05"/>
                    <measurement group_id="O2" value="2.29" lower_limit="-12.74" upper_limit="17.32"/>
                    <measurement group_id="O3" value="-10.14" lower_limit="-35.77" upper_limit="15.48"/>
                    <measurement group_id="O4" value="-0.13" lower_limit="-25.77" upper_limit="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.60" lower_limit="-30.67" upper_limit="1.47"/>
                    <measurement group_id="O2" value="14.85" lower_limit="-1.78" upper_limit="31.49"/>
                    <measurement group_id="O3" value="-8.10" lower_limit="-35.21" upper_limit="19.01"/>
                    <measurement group_id="O4" value="19.83" lower_limit="-7.29" upper_limit="46.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.05" lower_limit="-32.53" upper_limit="2.43"/>
                    <measurement group_id="O2" value="17.34" lower_limit="-0.75" upper_limit="35.44"/>
                    <measurement group_id="O3" value="-9.42" lower_limit="-37.40" upper_limit="18.57"/>
                    <measurement group_id="O4" value="20.47" lower_limit="-6.63" upper_limit="47.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="-22.83" upper_limit="25.56"/>
                    <measurement group_id="O2" value="46.05" lower_limit="20.87" upper_limit="71.22"/>
                    <measurement group_id="O3" value="12.22" lower_limit="-26.18" upper_limit="50.62"/>
                    <measurement group_id="O4" value="47.27" lower_limit="8.85" upper_limit="85.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Aldosterone Biomarker</title>
        <description>Aldosterone was analyzed at a central laboratory.</description>
        <time_frame>6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Aldosterone Biomarker</title>
          <description>Aldosterone was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.15" lower_limit="29.66" upper_limit="112.64"/>
                    <measurement group_id="O2" value="-14.63" lower_limit="-56.02" upper_limit="26.77"/>
                    <measurement group_id="O3" value="90.51" lower_limit="-39.10" upper_limit="220.12"/>
                    <measurement group_id="O4" value="72.92" lower_limit="-48.38" upper_limit="194.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.06" lower_limit="44.03" upper_limit="372.10"/>
                    <measurement group_id="O2" value="8.36" lower_limit="-155.05" upper_limit="171.77"/>
                    <measurement group_id="O3" value="249.13" lower_limit="4.30" upper_limit="493.96"/>
                    <measurement group_id="O4" value="325.31" lower_limit="96.75" upper_limit="553.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.32" lower_limit="65.01" upper_limit="271.63"/>
                    <measurement group_id="O2" value="71.73" lower_limit="-35.08" upper_limit="178.55"/>
                    <measurement group_id="O3" value="438.28" lower_limit="-67.61" upper_limit="944.17"/>
                    <measurement group_id="O4" value="524.93" lower_limit="55.45" upper_limit="994.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.21" lower_limit="16.31" upper_limit="206.11"/>
                    <measurement group_id="O2" value="21.68" lower_limit="-77.33" upper_limit="120.69"/>
                    <measurement group_id="O3" value="49.91" lower_limit="-12.58" upper_limit="112.40"/>
                    <measurement group_id="O4" value="5.61" lower_limit="-55.0" upper_limit="66.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.22" lower_limit="7.48" upper_limit="122.95"/>
                    <measurement group_id="O2" value="24.58" lower_limit="-31.70" upper_limit="80.87"/>
                    <measurement group_id="O3" value="24.47" lower_limit="-104.07" upper_limit="153.01"/>
                    <measurement group_id="O4" value="107.60" lower_limit="-16.47" upper_limit="231.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.32" lower_limit="-46.10" upper_limit="522.74"/>
                    <measurement group_id="O2" value="230.06" lower_limit="-58.04" upper_limit="518.17"/>
                    <measurement group_id="O3" value="147.89" lower_limit="-4.40" upper_limit="300.19"/>
                    <measurement group_id="O4" value="152.37" lower_limit="4.74" upper_limit="300.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)</title>
        <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium, potassium, albumin and calcium were measured.</description>
        <time_frame>2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)</title>
          <description>Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium, potassium, albumin and calcium were measured.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-1.24" upper_limit="1.13"/>
                    <measurement group_id="O2" value="-1.40" lower_limit="-2.62" upper_limit="-0.17"/>
                    <measurement group_id="O3" value="0.51" lower_limit="-1.00" upper_limit="2.01"/>
                    <measurement group_id="O4" value="0.08" lower_limit="-1.38" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" lower_limit="-3.78" upper_limit="-0.60"/>
                    <measurement group_id="O2" value="-2.46" lower_limit="-4.11" upper_limit="-0.81"/>
                    <measurement group_id="O3" value="0.76" lower_limit="-1.39" upper_limit="2.91"/>
                    <measurement group_id="O4" value="0.27" lower_limit="-1.79" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" lower_limit="-5.19" upper_limit="-2.19"/>
                    <measurement group_id="O2" value="-4.03" lower_limit="-5.59" upper_limit="-2.48"/>
                    <measurement group_id="O3" value="-2.22" lower_limit="-3.89" upper_limit="-0.55"/>
                    <measurement group_id="O4" value="-2.49" lower_limit="-4.10" upper_limit="-0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" lower_limit="-4.24" upper_limit="-1.37"/>
                    <measurement group_id="O2" value="-1.34" lower_limit="-2.83" upper_limit="0.16"/>
                    <measurement group_id="O3" value="1.77" lower_limit="-0.40" upper_limit="3.94"/>
                    <measurement group_id="O4" value="0.82" lower_limit="-1.27" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 2, 24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" lower_limit="-4.21" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.44" lower_limit="-1.72" upper_limit="2.60"/>
                    <measurement group_id="O3" value="2.06" lower_limit="-0.42" upper_limit="4.55"/>
                    <measurement group_id="O4" value="1.34" lower_limit="-1.06" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-2.75" upper_limit="2.07"/>
                    <measurement group_id="O2" value="-1.11" lower_limit="-3.60" upper_limit="1.38"/>
                    <measurement group_id="O3" value="-5.82" lower_limit="-8.28" upper_limit="-3.36"/>
                    <measurement group_id="O4" value="-6.19" lower_limit="-8.65" upper_limit="-3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" lower_limit="-4.09" upper_limit="-0.81"/>
                    <measurement group_id="O2" value="-2.17" lower_limit="-3.87" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-8.46" lower_limit="-10.95" upper_limit="-5.98"/>
                    <measurement group_id="O4" value="-7.42" lower_limit="-9.90" upper_limit="-4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.30" lower_limit="-5.65" upper_limit="-2.95"/>
                    <measurement group_id="O2" value="-3.53" lower_limit="-4.93" upper_limit="-2.12"/>
                    <measurement group_id="O3" value="-9.12" lower_limit="-11.54" upper_limit="-6.70"/>
                    <measurement group_id="O4" value="-9.89" lower_limit="-12.32" upper_limit="-7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.41" lower_limit="-4.94" upper_limit="-1.88"/>
                    <measurement group_id="O2" value="-1.27" lower_limit="-2.86" upper_limit="0.32"/>
                    <measurement group_id="O3" value="-4.63" lower_limit="-6.89" upper_limit="-2.36"/>
                    <measurement group_id="O4" value="-4.99" lower_limit="-7.25" upper_limit="-2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-1.05" upper_limit="0.39"/>
                    <measurement group_id="O2" value="-0.47" lower_limit="-1.22" upper_limit="0.28"/>
                    <measurement group_id="O3" value="-0.35" lower_limit="-0.96" upper_limit="0.27"/>
                    <measurement group_id="O4" value="0.22" lower_limit="-0.38" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" lower_limit="-2.07" upper_limit="-0.64"/>
                    <measurement group_id="O2" value="-0.61" lower_limit="-1.36" upper_limit="0.14"/>
                    <measurement group_id="O3" value="0.05" lower_limit="-0.62" upper_limit="0.72"/>
                    <measurement group_id="O4" value="0.41" lower_limit="-0.23" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" lower_limit="-1.35" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-0.42" lower_limit="-1.14" upper_limit="0.30"/>
                    <measurement group_id="O3" value="-0.48" lower_limit="-1.15" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.05" lower_limit="-0.59" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="-0.49" upper_limit="1.41"/>
                    <measurement group_id="O2" value="1.44" lower_limit="0.45" upper_limit="2.42"/>
                    <measurement group_id="O3" value="-0.93" lower_limit="-1.70" upper_limit="-0.16"/>
                    <measurement group_id="O4" value="-0.15" lower_limit="-0.92" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 2, 24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="-0.23" upper_limit="1.22"/>
                    <measurement group_id="O2" value="0.73" lower_limit="-0.02" upper_limit="1.48"/>
                    <measurement group_id="O3" value="0.11" lower_limit="-0.82" upper_limit="1.04"/>
                    <measurement group_id="O4" value="0.58" lower_limit="-0.34" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="0.40" upper_limit="2.53"/>
                    <measurement group_id="O2" value="1.28" lower_limit="0.19" upper_limit="2.37"/>
                    <measurement group_id="O3" value="0.89" lower_limit="0.17" upper_limit="1.62"/>
                    <measurement group_id="O4" value="0.63" lower_limit="-0.09" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="-0.96" upper_limit="1.89"/>
                    <measurement group_id="O2" value="0.22" lower_limit="-1.26" upper_limit="1.69"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.86" upper_limit="0.75"/>
                    <measurement group_id="O4" value="0.28" lower_limit="-0.50" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="-0.29" upper_limit="2.03"/>
                    <measurement group_id="O2" value="1.32" lower_limit="0.11" upper_limit="2.52"/>
                    <measurement group_id="O3" value="-0.21" lower_limit="-1.00" upper_limit="0.58"/>
                    <measurement group_id="O4" value="-0.86" lower_limit="-1.68" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="-0.12" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.06" upper_limit="2.35"/>
                    <measurement group_id="O3" value="-1.16" lower_limit="-2.08" upper_limit="-0.25"/>
                    <measurement group_id="O4" value="-1.48" lower_limit="-2.43" upper_limit="-0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="-0.71" upper_limit="4.63"/>
                    <measurement group_id="O2" value="-1.25" lower_limit="-4.01" upper_limit="1.51"/>
                    <measurement group_id="O3" value="-1.20" lower_limit="-3.86" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.69" lower_limit="-0.86" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" lower_limit="-3.73" upper_limit="3.41"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-3.80" upper_limit="3.58"/>
                    <measurement group_id="O3" value="0.42" lower_limit="-6.10" upper_limit="6.95"/>
                    <measurement group_id="O4" value="1.11" lower_limit="-5.17" upper_limit="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.91" lower_limit="-5.82" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-5.88" lower_limit="-8.90" upper_limit="-2.87"/>
                    <measurement group_id="O3" value="-0.63" lower_limit="-8.29" upper_limit="7.02"/>
                    <measurement group_id="O4" value="-2.61" lower_limit="-10.00" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" lower_limit="-0.02" upper_limit="13.28"/>
                    <measurement group_id="O2" value="15.27" lower_limit="8.40" upper_limit="22.15"/>
                    <measurement group_id="O3" value="18.57" lower_limit="10.49" upper_limit="26.64"/>
                    <measurement group_id="O4" value="19.96" lower_limit="11.85" upper_limit="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 2, 24.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" lower_limit="-1.44" upper_limit="5.56"/>
                    <measurement group_id="O2" value="0.14" lower_limit="-3.48" upper_limit="3.76"/>
                    <measurement group_id="O3" value="7.70" lower_limit="1.23" upper_limit="14.18"/>
                    <measurement group_id="O4" value="7.00" lower_limit="0.51" upper_limit="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="-2.80" upper_limit="4.93"/>
                    <measurement group_id="O2" value="-1.55" lower_limit="-5.55" upper_limit="2.45"/>
                    <measurement group_id="O3" value="-0.47" lower_limit="-4.70" upper_limit="3.76"/>
                    <measurement group_id="O4" value="1.29" lower_limit="-2.93" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" lower_limit="-5.21" upper_limit="0.89"/>
                    <measurement group_id="O2" value="-2.93" lower_limit="-6.08" upper_limit="0.22"/>
                    <measurement group_id="O3" value="3.61" lower_limit="-5.71" upper_limit="12.94"/>
                    <measurement group_id="O4" value="0.28" lower_limit="-8.60" upper_limit="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" lower_limit="-6.47" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-5.16" lower_limit="-8.49" upper_limit="-1.84"/>
                    <measurement group_id="O3" value="-4.20" lower_limit="-10.85" upper_limit="2.45"/>
                    <measurement group_id="O4" value="-4.14" lower_limit="-11.06" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.22" lower_limit="9.58" upper_limit="24.86"/>
                    <measurement group_id="O2" value="12.32" lower_limit="4.37" upper_limit="20.26"/>
                    <measurement group_id="O3" value="18.19" lower_limit="7.38" upper_limit="29.01"/>
                    <measurement group_id="O4" value="19.28" lower_limit="8.12" upper_limit="30.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" lower_limit="-1.68" upper_limit="-0.50"/>
                    <measurement group_id="O2" value="-0.67" lower_limit="-1.28" upper_limit="-0.05"/>
                    <measurement group_id="O3" value="-0.63" lower_limit="-1.10" upper_limit="-0.16"/>
                    <measurement group_id="O4" value="-0.17" lower_limit="-0.63" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" lower_limit="-2.52" upper_limit="-1.13"/>
                    <measurement group_id="O2" value="-1.18" lower_limit="-1.90" upper_limit="-0.45"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-0.84" upper_limit="0.48"/>
                    <measurement group_id="O4" value="-0.04" lower_limit="-0.67" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 1, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" lower_limit="-2.09" upper_limit="-0.84"/>
                    <measurement group_id="O2" value="-1.12" lower_limit="-1.77" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-0.62" lower_limit="-1.20" upper_limit="-0.04"/>
                    <measurement group_id="O4" value="-0.17" lower_limit="-0.73" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.74" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.48" lower_limit="-0.11" upper_limit="1.07"/>
                    <measurement group_id="O3" value="-0.12" lower_limit="-0.91" upper_limit="0.68"/>
                    <measurement group_id="O4" value="0.14" lower_limit="-0.66" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 2, 24.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.78" upper_limit="0.84"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.22" upper_limit="1.90"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.24" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.24" lower_limit="0.63" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="0.23" upper_limit="2.18"/>
                    <measurement group_id="O2" value="1.36" lower_limit="0.35" upper_limit="2.37"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.05" upper_limit="1.33"/>
                    <measurement group_id="O4" value="0.84" lower_limit="0.20" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-1.46" upper_limit="0.95"/>
                    <measurement group_id="O2" value="-0.89" lower_limit="-2.14" upper_limit="0.37"/>
                    <measurement group_id="O3" value="-0.81" lower_limit="-1.57" upper_limit="-0.05"/>
                    <measurement group_id="O4" value="-0.16" lower_limit="-0.89" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 7, 6.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-1.17" upper_limit="1.19"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-1.42" upper_limit="1.05"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-1.36" upper_limit="-0.13"/>
                    <measurement group_id="O4" value="-0.86" lower_limit="-1.49" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="-0.62" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.78" lower_limit="-0.22" upper_limit="1.77"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-1.23" upper_limit="0.42"/>
                    <measurement group_id="O4" value="-1.04" lower_limit="-1.89" upper_limit="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Blood Plasma Creatinine</title>
        <description>Blood plasma creatinine was analyzed at a central laboratory.</description>
        <time_frame>4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Blood Plasma Creatinine</title>
          <description>Blood plasma creatinine was analyzed at a central laboratory.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" lower_limit="-9.03" upper_limit="-5.10"/>
                    <measurement group_id="O2" value="-3.55" lower_limit="-5.56" upper_limit="-1.54"/>
                    <measurement group_id="O3" value="-7.48" lower_limit="-9.28" upper_limit="-5.68"/>
                    <measurement group_id="O4" value="-0.91" lower_limit="-2.65" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" lower_limit="-5.49" upper_limit="-0.46"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-2.67" upper_limit="2.54"/>
                    <measurement group_id="O3" value="-1.72" lower_limit="-5.41" upper_limit="1.96"/>
                    <measurement group_id="O4" value="4.40" lower_limit="0.84" upper_limit="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="-1.96" upper_limit="8.00"/>
                    <measurement group_id="O2" value="5.36" lower_limit="0.21" upper_limit="10.52"/>
                    <measurement group_id="O3" value="6.22" lower_limit="1.90" upper_limit="10.54"/>
                    <measurement group_id="O4" value="9.23" lower_limit="5.07" upper_limit="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" lower_limit="-1.37" upper_limit="8.83"/>
                    <measurement group_id="O2" value="4.02" lower_limit="-1.26" upper_limit="9.30"/>
                    <measurement group_id="O3" value="13.64" lower_limit="8.44" upper_limit="18.84"/>
                    <measurement group_id="O4" value="6.18" lower_limit="1.15" upper_limit="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="-6.71" upper_limit="15.19"/>
                    <measurement group_id="O2" value="0.55" lower_limit="-10.43" upper_limit="11.52"/>
                    <measurement group_id="O3" value="1.76" lower_limit="-1.74" upper_limit="5.27"/>
                    <measurement group_id="O4" value="1.71" lower_limit="-1.79" upper_limit="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" lower_limit="-8.56" upper_limit="5.63"/>
                    <measurement group_id="O2" value="-5.09" lower_limit="-12.26" upper_limit="2.07"/>
                    <measurement group_id="O3" value="-3.02" lower_limit="-6.71" upper_limit="0.68"/>
                    <measurement group_id="O4" value="-1.28" lower_limit="-4.98" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.0 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="-6.15" upper_limit="9.59"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-8.18" upper_limit="7.68"/>
                    <measurement group_id="O3" value="0.48" lower_limit="-3.44" upper_limit="4.40"/>
                    <measurement group_id="O4" value="3.03" lower_limit="-0.89" upper_limit="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" lower_limit="-3.02" upper_limit="19.07"/>
                    <measurement group_id="O2" value="8.34" lower_limit="-2.79" upper_limit="19.48"/>
                    <measurement group_id="O3" value="9.33" lower_limit="4.43" upper_limit="14.24"/>
                    <measurement group_id="O4" value="4.55" lower_limit="-0.35" upper_limit="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) Over Time</title>
        <description>GFR was used as a measure of renal function.</description>
        <time_frame>0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) Over Time</title>
          <description>GFR was used as a measure of renal function.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="43.27"/>
                    <measurement group_id="O2" value="92.5" spread="97.37"/>
                    <measurement group_id="O3" value="87.6" spread="64.27"/>
                    <measurement group_id="O4" value="99.2" spread="66.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.7" spread="57.89"/>
                    <measurement group_id="O2" value="83.3" spread="46.57"/>
                    <measurement group_id="O3" value="112.1" spread="63.30"/>
                    <measurement group_id="O4" value="96.0" spread="44.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.4" spread="75.09"/>
                    <measurement group_id="O2" value="70.9" spread="36.64"/>
                    <measurement group_id="O3" value="125.4" spread="95.33"/>
                    <measurement group_id="O4" value="101.8" spread="65.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="68.73"/>
                    <measurement group_id="O2" value="71.7" spread="37.27"/>
                    <measurement group_id="O3" value="148.4" spread="138.66"/>
                    <measurement group_id="O4" value="123.0" spread="60.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="75.98"/>
                    <measurement group_id="O2" value="87.8" spread="57.47"/>
                    <measurement group_id="O3" value="96.8" spread="78.65"/>
                    <measurement group_id="O4" value="83.2" spread="53.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="39.47"/>
                    <measurement group_id="O2" value="83.1" spread="35.65"/>
                    <measurement group_id="O3" value="133.5" spread="67.82"/>
                    <measurement group_id="O4" value="91.4" spread="50.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="52.23"/>
                    <measurement group_id="O2" value="94.6" spread="53.43"/>
                    <measurement group_id="O3" value="151.7" spread="109.91"/>
                    <measurement group_id="O4" value="111.3" spread="59.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="49.26"/>
                    <measurement group_id="O2" value="126.6" spread="79.95"/>
                    <measurement group_id="O3" value="111.5" spread="66.30"/>
                    <measurement group_id="O4" value="165.2" spread="228.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Blood Flow (RBF) Over Time</title>
        <description>RBF was used as a measure of renal function.</description>
        <time_frame>0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Blood Flow (RBF) Over Time</title>
          <description>RBF was used as a measure of renal function.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.1" spread="221.24"/>
                    <measurement group_id="O2" value="305.7" spread="159.44"/>
                    <measurement group_id="O3" value="774.7" spread="893.23"/>
                    <measurement group_id="O4" value="737.0" spread="323.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.3" spread="171.80"/>
                    <measurement group_id="O2" value="357.4" spread="218.28"/>
                    <measurement group_id="O3" value="570.5" spread="212.67"/>
                    <measurement group_id="O4" value="541.7" spread="179.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.1" spread="169.87"/>
                    <measurement group_id="O2" value="297.4" spread="219.83"/>
                    <measurement group_id="O3" value="700.0" spread="408.73"/>
                    <measurement group_id="O4" value="573.4" spread="287.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.2" spread="276.84"/>
                    <measurement group_id="O2" value="290.05" spread="138.30"/>
                    <measurement group_id="O3" value="1165.2" spread="912.25"/>
                    <measurement group_id="O4" value="758.7" spread="375.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.9" spread="223.49"/>
                    <measurement group_id="O2" value="417.0" spread="254.35"/>
                    <measurement group_id="O3" value="548.5" spread="389.77"/>
                    <measurement group_id="O4" value="549.3" spread="247.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.9" spread="180.59"/>
                    <measurement group_id="O2" value="341.1" spread="156.86"/>
                    <measurement group_id="O3" value="630.4" spread="239.55"/>
                    <measurement group_id="O4" value="659.1" spread="426.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.2" spread="168.10"/>
                    <measurement group_id="O2" value="285.9" spread="150.82"/>
                    <measurement group_id="O3" value="653.2" spread="412.91"/>
                    <measurement group_id="O4" value="606.3" spread="224.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.0" spread="228.38"/>
                    <measurement group_id="O2" value="440.8" spread="310.64"/>
                    <measurement group_id="O3" value="667.6" spread="308.52"/>
                    <measurement group_id="O4" value="977.9" spread="975.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Systolic Blood Pressure</title>
        <description>Systolic blood pressure measurements were taken.</description>
        <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Systolic Blood Pressure</title>
          <description>Systolic blood pressure measurements were taken.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.8" spread="14.10"/>
                    <measurement group_id="O2" value="127.0" spread="16.62"/>
                    <measurement group_id="O3" value="136.1" spread="18.80"/>
                    <measurement group_id="O4" value="133.2" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.8" spread="14.36"/>
                    <measurement group_id="O2" value="121.5" spread="21.78"/>
                    <measurement group_id="O3" value="132.9" spread="19.52"/>
                    <measurement group_id="O4" value="132.5" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.9" spread="16.53"/>
                    <measurement group_id="O2" value="122.2" spread="19.20"/>
                    <measurement group_id="O3" value="134.1" spread="18.57"/>
                    <measurement group_id="O4" value="133.2" spread="15.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.4" spread="13.68"/>
                    <measurement group_id="O2" value="127.2" spread="16.71"/>
                    <measurement group_id="O3" value="134.2" spread="19.85"/>
                    <measurement group_id="O4" value="132.6" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.1" spread="18.65"/>
                    <measurement group_id="O2" value="130.3" spread="17.14"/>
                    <measurement group_id="O3" value="140.7" spread="20.67"/>
                    <measurement group_id="O4" value="142.1" spread="17.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.6" spread="13.29"/>
                    <measurement group_id="O2" value="120.9" spread="16.85"/>
                    <measurement group_id="O3" value="127.3" spread="17.39"/>
                    <measurement group_id="O4" value="132.2" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.1" spread="14.75"/>
                    <measurement group_id="O2" value="114.8" spread="17.85"/>
                    <measurement group_id="O3" value="127.4" spread="13.92"/>
                    <measurement group_id="O4" value="134.1" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.8" spread="9.61"/>
                    <measurement group_id="O2" value="120.9" spread="18.05"/>
                    <measurement group_id="O3" value="125.4" spread="12.66"/>
                    <measurement group_id="O4" value="128.9" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.5" spread="10.03"/>
                    <measurement group_id="O2" value="115.9" spread="15.47"/>
                    <measurement group_id="O3" value="128.9" spread="14.83"/>
                    <measurement group_id="O4" value="128.8" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.2" spread="10.93"/>
                    <measurement group_id="O2" value="122.9" spread="11.78"/>
                    <measurement group_id="O3" value="127.4" spread="16.26"/>
                    <measurement group_id="O4" value="130.9" spread="15.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.9" spread="10.01"/>
                    <measurement group_id="O2" value="124.8" spread="12.43"/>
                    <measurement group_id="O3" value="127.4" spread="17.46"/>
                    <measurement group_id="O4" value="130.9" spread="15.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.3" spread="12.70"/>
                    <measurement group_id="O2" value="127.5" spread="11.95"/>
                    <measurement group_id="O3" value="128.6" spread="19.35"/>
                    <measurement group_id="O4" value="140.7" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.6" spread="11.71"/>
                    <measurement group_id="O2" value="128.9" spread="13.13"/>
                    <measurement group_id="O3" value="130.5" spread="18.15"/>
                    <measurement group_id="O4" value="134.9" spread="13.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.3" spread="12.52"/>
                    <measurement group_id="O2" value="119.3" spread="10.44"/>
                    <measurement group_id="O3" value="123.1" spread="12.72"/>
                    <measurement group_id="O4" value="130.0" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.9" spread="16.70"/>
                    <measurement group_id="O2" value="116.5" spread="14.85"/>
                    <measurement group_id="O3" value="120.3" spread="12.60"/>
                    <measurement group_id="O4" value="131.9" spread="18.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Diastolic Blood Pressure</title>
        <description>Diastolic blood pressure measurements were taken.</description>
        <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Diastolic Blood Pressure</title>
          <description>Diastolic blood pressure measurements were taken.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="9.85"/>
                    <measurement group_id="O2" value="74.1" spread="13.20"/>
                    <measurement group_id="O3" value="77.6" spread="10.57"/>
                    <measurement group_id="O4" value="74.9" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="12.00"/>
                    <measurement group_id="O2" value="75.5" spread="13.77"/>
                    <measurement group_id="O3" value="76.3" spread="11.85"/>
                    <measurement group_id="O4" value="75.8" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="12.00"/>
                    <measurement group_id="O2" value="75.8" spread="13.73"/>
                    <measurement group_id="O3" value="75.3" spread="10.37"/>
                    <measurement group_id="O4" value="76.2" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="12.01"/>
                    <measurement group_id="O2" value="77.1" spread="10.61"/>
                    <measurement group_id="O3" value="77.6" spread="11.79"/>
                    <measurement group_id="O4" value="76.0" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="13.77"/>
                    <measurement group_id="O2" value="79.1" spread="12.21"/>
                    <measurement group_id="O3" value="80.0" spread="13.60"/>
                    <measurement group_id="O4" value="79.9" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="11.15"/>
                    <measurement group_id="O2" value="70.4" spread="11.12"/>
                    <measurement group_id="O3" value="75.2" spread="10.23"/>
                    <measurement group_id="O4" value="76.2" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="11.49"/>
                    <measurement group_id="O2" value="71.7" spread="13.43"/>
                    <measurement group_id="O3" value="75.5" spread="8.33"/>
                    <measurement group_id="O4" value="75.7" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="10.03"/>
                    <measurement group_id="O2" value="74.9" spread="13.33"/>
                    <measurement group_id="O3" value="73.2" spread="10.78"/>
                    <measurement group_id="O4" value="75.1" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="11.04"/>
                    <measurement group_id="O2" value="68.4" spread="11.37"/>
                    <measurement group_id="O3" value="74.7" spread="8.77"/>
                    <measurement group_id="O4" value="74.7" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="11.74"/>
                    <measurement group_id="O2" value="73.9" spread="9.48"/>
                    <measurement group_id="O3" value="74.3" spread="9.36"/>
                    <measurement group_id="O4" value="74.5" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="10.49"/>
                    <measurement group_id="O2" value="73.9" spread="8.94"/>
                    <measurement group_id="O3" value="73.5" spread="8.52"/>
                    <measurement group_id="O4" value="75.1" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread="11.85"/>
                    <measurement group_id="O2" value="76.7" spread="9.15"/>
                    <measurement group_id="O3" value="72.0" spread="8.20"/>
                    <measurement group_id="O4" value="78.8" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="11.17"/>
                    <measurement group_id="O2" value="74.5" spread="10.86"/>
                    <measurement group_id="O3" value="74.4" spread="9.60"/>
                    <measurement group_id="O4" value="78.4" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="10.08"/>
                    <measurement group_id="O2" value="71.5" spread="8.43"/>
                    <measurement group_id="O3" value="71.4" spread="7.84"/>
                    <measurement group_id="O4" value="75.3" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="10.95"/>
                    <measurement group_id="O2" value="69.8" spread="12.39"/>
                    <measurement group_id="O3" value="70.7" spread="8.36"/>
                    <measurement group_id="O4" value="75.7" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Pulse Rate</title>
        <description>Pulse rate measurements were taken.</description>
        <time_frame>0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7</time_frame>
        <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 - Heart Failure (HF) Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O2">
            <title>Valsartan - HF Cohort</title>
            <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 - Hypertension (HTN) Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
          </group>
          <group group_id="O4">
            <title>Valsartan - HTN Cohort</title>
            <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Pulse Rate</title>
          <description>Pulse rate measurements were taken.</description>
          <population>The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.</population>
          <units>BPM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="8.89"/>
                    <measurement group_id="O2" value="61.7" spread="14.30"/>
                    <measurement group_id="O3" value="65.7" spread="9.26"/>
                    <measurement group_id="O4" value="65.5" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="9.34"/>
                    <measurement group_id="O2" value="60.7" spread="10.45"/>
                    <measurement group_id="O3" value="64.1" spread="8.59"/>
                    <measurement group_id="O4" value="63.4" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" spread="8.97"/>
                    <measurement group_id="O2" value="62.7" spread="10.19"/>
                    <measurement group_id="O3" value="64.2" spread="7.49"/>
                    <measurement group_id="O4" value="64.0" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="9.02"/>
                    <measurement group_id="O2" value="64.3" spread="12.39"/>
                    <measurement group_id="O3" value="65.6" spread="8.28"/>
                    <measurement group_id="O4" value="63.2" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="8.51"/>
                    <measurement group_id="O2" value="62.9" spread="13.29"/>
                    <measurement group_id="O3" value="64.0" spread="6.51"/>
                    <measurement group_id="O4" value="65.3" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" spread="11.70"/>
                    <measurement group_id="O2" value="69.1" spread="11.34"/>
                    <measurement group_id="O3" value="73.9" spread="10.20"/>
                    <measurement group_id="O4" value="67.5" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" spread="13.36"/>
                    <measurement group_id="O2" value="62.8" spread="10.83"/>
                    <measurement group_id="O3" value="73.7" spread="13.52"/>
                    <measurement group_id="O4" value="65.4" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="12.18"/>
                    <measurement group_id="O2" value="64.5" spread="11.95"/>
                    <measurement group_id="O3" value="71.3" spread="10.58"/>
                    <measurement group_id="O4" value="66.5" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="11.97"/>
                    <measurement group_id="O2" value="60.6" spread="12.69"/>
                    <measurement group_id="O3" value="62.9" spread="5.54"/>
                    <measurement group_id="O4" value="62.8" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="12.63"/>
                    <measurement group_id="O2" value="60.1" spread="12.07"/>
                    <measurement group_id="O3" value="63.0" spread="4.36"/>
                    <measurement group_id="O4" value="61.8" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.0 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="13.21"/>
                    <measurement group_id="O2" value="61.6" spread="11.70"/>
                    <measurement group_id="O3" value="62.3" spread="5.87"/>
                    <measurement group_id="O4" value="61.6" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="10.42"/>
                    <measurement group_id="O2" value="58.7" spread="11.49"/>
                    <measurement group_id="O3" value="61.2" spread="6.17"/>
                    <measurement group_id="O4" value="63.6" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="10.85"/>
                    <measurement group_id="O2" value="60.7" spread="11.34"/>
                    <measurement group_id="O3" value="62.9" spread="6.45"/>
                    <measurement group_id="O4" value="62.7" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="10.20"/>
                    <measurement group_id="O2" value="66.5" spread="11.80"/>
                    <measurement group_id="O3" value="66.3" spread="7.34"/>
                    <measurement group_id="O4" value="64.8" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.0 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="13.28"/>
                    <measurement group_id="O2" value="71.9" spread="17.30"/>
                    <measurement group_id="O3" value="66.2" spread="6.97"/>
                    <measurement group_id="O4" value="67.1" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 - Heart Failure (HF) Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="E2">
          <title>Valsartan - HF Cohort</title>
          <description>Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.</description>
        </group>
        <group group_id="E3">
          <title>LCZ696 - Hypertension (HTN) Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.</description>
        </group>
        <group group_id="E4">
          <title>Valsartan - HTN Cohort</title>
          <description>Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Regarding LSM = 1218.56 for LCZ696 HTN cohort arm at Day 1, 1.0 hr post dose, the value was heavily inflated due to one participant with a very high change from baseline.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-1873</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

